Additionally, Bispecific antibodies (BsAbs) simultaneously blocking the CD47-SIRPα axis and binding to the tumor-specific antigen (CD20) have shown promising efficacy with less blood cell destruction in a human NHL-engrafted mouse model (44). This evidence concerns the gene CD47 and neoplasm.